Johnson & Johnson's TREMFYA (guselkumab) demonstrated consistent combined fistula remission rates of up to 28% at Week 24 in adults with Crohn's disease and perianal fistula, outperforming placebo at 10%. New Phase 3 subgroup analyses from the FUZION study showed efficacy across patients with prior biologic exposure, varying disease activity, and presence or absence of proctitis. This marks the first positive dedicated randomized trial in over 20 years for this difficult-to-treat condition, addressing a significant unmet medical need. TREMFYA's safety profile remained consistent with previous findings, supporting its potential as a treatment option for complex Crohn's disease cases.
Johnson & Johnson's stock price on Pluang is USD 264.37 as of Oct 13, 2026, 03:02 WIB, showing a 1.12% increase in one day. The company holds a substantial market cap of $630.04 billion, reflecting its significant presence in the health sector. Despite the positive clinical trial news, the majority of Pluang users are selling JNJ shares, with 84% of order activity being sell orders at this time.
Johnson & Johnson announced three-year data from Phase 3 GALAXI 2 and 3 studies showing TREMFYA (guselkumab) provides durable clinical remission rates up to 94% and endoscopic remission up to 61% in adults with moderately to severely active Crohn's d...
As of October 2026, U.S. Treasury bills yield between 3.98% and 4.44% depending on maturity, surpassing Johnson & Johnson's 2.05% dividend yield. Treasury bills guarantee fixed returns until maturity but carry reinvestment and inflation risks, while ...
Johnson & Johnson and UnitedHealth Group both released their third-quarter 2026 earnings on the same morning, highlighting key trends in drug costs, insurance margins, and sector outlook. Johnson & Johnson showed steady revenue growth with strong per...
Johnson & Johnson will report its Q3 2026 earnings on October 13, with analysts expecting earnings per share (EPS) of $2.66, a 5% decline from last year, while revenue is forecasted to grow 5.8% to $25.40 billion. Despite the EPS drop, the company ha...
Four Dividend Kings—Johnson & Johnson, Procter & Gamble, Coca-Cola, and PepsiCo—continue to deliver steady dividends, crucial for retirees relying on portfolio income. Johnson & Johnson and Procter & Gamble show very safe dividend payouts with health...
